Bausch + Lomb issued the recall after the company received reports of toxic anterior segment syndrome, or an inflammatory reaction inside the eye.

Bausch + Lomb addresses recent IOL recall, ensuring safety with enhanced protocols and returning enVista lenses to market ...

Bausch + Lomb announced today that it intends to bring its recently recalled enVista intraocular lenses (IOLs) back to the ...

The recall was issued in response to reports of toxic anterior segment syndrome, or TASS, an acute sterile anterior chamber inflammatory reaction that usually develops 12 to 48 hours after surgery.

The company said it was recalling several of its enVista lenses because it received reports of toxic anterior segment syndrome or TASS. The recall affects the company’s enVista Aspire and ...

Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 21.2% in the morning session after the company reported weak first ...

Bausch + Lomb Corporation issued a recall for multiple models of eye implants in its enVista platform after "an increased number of reports of toxic anterior segment syndrome (TASS)," per the recall.

An analysis of the timing of adverse event reports has convinced the company that raw material delivered by a vendor was the ...

Bausch + Lomb will return its enVista intraocular lenses to market following a voluntary recall in March after discovering they had certain production and material issues.

The company recalled the products after receiving an increased number of reports of toxic anterior segment syndrome (TASS), an inflammatory reaction of the anterior segment of the eye.